Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14902]

Meta-analysis shows targeted radiation therapy may be as effective as standard care for small cell lung cancer patients with brain metastases

Meta-analysis shows targeted radiation therapy may be as effective as standard care for small cell lung cancer...

ECOG-ACRIN research highlights at ASCO 2022

ECOG-ACRIN research highlights at ASCO 2022

Open-label placebo treatment reduces cancer-related fatigue in patients with advanced cancers

Open-label placebo treatment reduces cancer-related fatigue in patients with advanced cancers

ASCO 2022: Acupuncture improves chronic radiation-induced dry mouth for patients with head and neck cancer

ASCO 2022: Acupuncture improves chronic radiation-induced dry mouth for patients with head and neck cancer

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma

ASCO 2022: Patient-facing screening tool could increase detection of individuals with inherited cancer risk

ASCO 2022: Patient-facing screening tool could increase detection of individuals with inherited cancer risk

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast...

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+ breast cancer, study finds

ASCO 2022: Endocrine sensitivity test predicts survival benefit of dose-dense chemotherapy for patients with HR+...

ASCO 2022: Immunotherapy drug combination is safe with promising results in glioblastoma

ASCO 2022: Immunotherapy drug combination is safe with promising results in glioblastoma

More from ecancer